Mechanisms of Resistance to Noncovalent BTK Inhibitors in CLL
Skye Montoya, discusses research that she was a part of on mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Breaking Down Resistance to BTK Inhibitors
New research of the BTK degrader NX-2127 shows promising results for breaking down resistance to the therapy in the lymphoma and leukemia settings.
2 Commerce Drive Cranbury, NJ 08512